These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 12806570

  • 41. Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment-resistant schizoaffective disorder.
    Xu JJ, Xiao C, Pan Y, Tang YL, Wang M, Li S, Xie G, Du J, Ren Y, Wang W.
    Bipolar Disord; 2024 Feb; 26(1):95-97. PubMed ID: 38097824
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. [Relationship between clozapine plasma levels and withdrawal symptoms].
    Berecz R, de la Rubia Martínez A, Norberto Gamero MJ, Gutiérrez Casares JR, Glaub T, Degrell I, Llerena A.
    Actas Esp Psiquiatr; 2002 Feb; 30(6):397-9. PubMed ID: 12487951
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. [Antipsychotic efficacy in relation to plasma levels of clozapine (author's transl)].
    Ackenheil M, Bräu H, Burkhart A, Franke A, Pacha W.
    Arzneimittelforschung; 1976 Feb; 26(6):1156-8. PubMed ID: 989406
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Prescribing and monitoring clozapine in Christchurch.
    McKean A, Vella-Brincat J, Begg E.
    Australas Psychiatry; 2008 Aug; 16(4):263-7. PubMed ID: 18668375
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables.
    Diaz FJ, Santoro V, Spina E, Cogollo M, Rivera TE, Botts S, de Leon J.
    Pharmacopsychiatry; 2008 May; 41(3):81-91. PubMed ID: 18484549
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ.
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [Abstract] [Full Text] [Related]

  • 52. A review of the use of clozapine levels to guide treatment and determine cause of death.
    Stark A, Scott J.
    Aust N Z J Psychiatry; 2012 Sep; 46(9):816-25. PubMed ID: 22327098
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. The clinical use of plasma clozapine levels.
    Bell R, McLaren A, Galanos J, Copolov D.
    Aust N Z J Psychiatry; 1998 Aug; 32(4):567-74. PubMed ID: 9711372
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Elevated clozapine plasma concentration secondary to a urinary tract infection: proposed mechanisms.
    Lee LH, White RF, Barr AM, Honer WG, Procyshyn RM.
    J Psychiatry Neurosci; 2016 Jun; 41(4):E67-8. PubMed ID: 27332768
    [No Abstract] [Full Text] [Related]

  • 59. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.
    van der Weide J, Steijns LS, van Weelden MJ.
    Pharmacogenetics; 2003 Mar; 13(3):169-72. PubMed ID: 12618594
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.